• Cabozantinib is the first and only monotherapy to demonstrate superior clinical efficacy over sunitinib in treatment-naïve patients with intermediate- or poor-risk aRCC

• Independent Radiology Review Committee confirms primary endpoint analysis per investigator: cabozantinib provided statistically significant improvement of progression-free survival, with a 52 percent reduction in the rate of progression or death compared to sunitinib
• Ipsen and Exelixis will host an investor and media webcast from Madrid to discuss the data on Sunday, September 10 starting at 18h45 CEST

• Positive opinion based on the results of two randomized Phase 3 trials, TELESTAR and TELECAST

Saol sales team to promote Dysport^® for select approved therapeutic indications  in U.S. hospitals

IRC confirms cabozantinib significantly improved progression-free survival compared to sunitinib

E.U. regulatory submission remains on track for Q3 2017

Adoption of all resolutions submitted to the vote of Shareholders

2020 sales to exceed €2.5 billion
driven by Specialty Care sales growth above 14% per year¹ with a Group Core Operating Income margin greater than 30% of sales

“Primary Care” division to become “Consumer Healthcare”

Strong operating performance exceeds guidance with Group sales up 11.8% driven by Specialty Care and Core Operating Margin improvement despite Cabometyx launch investments

Acquisition of Onivyde and new Primary Care products expected to close during the first half of 2017

Transaction leverages Primary Care infrastructure and accelerates conversion to OTx business model.

Ipsen to pay €83 million cash upon closing for the products.

Ipsen today announced the appointment of Harout Semerjian as President, Head of Specialty Care International Region & Global Franchises, effective February 2, 2017. He will report to David Meek, CEO of Ipsen, and will be a member of the Executive Leadership Team.

Under the terms of the agreement, Ipsen will gain exclusive commercialization rights for the current and potential future ONIVYDE indications in the U.S., as well as the current licensing agreements with Shire for commercialization rights ex-U.S. and PharmaEngine for Taiwan. The transaction also includes Merrimack’s commercial and manufacturing infrastructure, and generic doxorubicin HCl liposome injection.

• Amendment enhances productive year with CABOMETYX^TM regulatory approvals and commercial launches in the United States and European Union
• Exelixis to receive $10 million upfront payment, with subsequent regulatory and commercial milestones

Ipsen (Euronext: IPN; ADR: IPSEY) announced today its corporate agenda* for 2017: 

Alexandre Lebeaut, MD will lead the R&D division in the interim.

• Acceleration of Group sales growth at 12.2%¹ in the third quarter resulting in 10.5%¹ sales growth for the first 9 months driven by Specialty Care
• Guidance 2016 raised

The 2016 Georges Mathé Prize was presented on October 10, 2016 during the ESMO (European Society of Medical Oncology) meeting in Copenhagen. The Prize, supporting translational research of excellence, was established in memory of the pioneer of cancer research in France, Georges Mathé, deceased in 2010. The Prize was awarded to a young Greek researcher, Doctor Alexios Matikas, a clinical oncologist from the University Hospital Heraklion, for his research project on immunological determinants of response to treatment in breast cancer. The Fellowship will support his research in Karolinska Institutet (Stockholm, Sweden), into the immunological determinants of response to treatment in breast cancer.

• Cabozantinib met the primary endpoint of improving progression-free survival as compared to sunitinib, decreasing the rate of disease progression or death by 31 percent
• Objective response rate significantly improved: 46 percent for cabozantinib versus 18 percent for sunitinib
• Ipsen to host investor and media webcast from Copenhagen to discuss the data on Monday, October 10

Ipsen, a global specialty-driven pharmaceutical group, today announced that Cabometyx™ (cabozantinib),  Somatuline^® Autogel^® (lanreotide) and telotristat ethyl (*previously known as telotristat etiprate) will be the subject of 16 presentations at the European Society for Medical Oncology (ESMO) 2016 congress.

• Cabometyx™ (cabozantinib) is the first and only targeted therapy to improve Overall Survival (OS), Objective Response Rate (ORR), and Progression Free Survival (PFS) in RCC in METEOR randomized Phase 3 trial.
• Cabometyx™ (cabozantinib) improves OS across all evaluated patient subgroups.
• Cabometyx™ (cabozantinib) has a unique mechanism of action with the potential to overcome resistance to VEGFR tyrosine kinase inhibitors.

First and only FDA-approved botulinum toxin for the treatment of pediatric lower limb spasticity.

• Group sales up 9.7%¹ driven by Specialty Care growth of 14.3%¹ , notably due to strong performance of Somatuline^®
• Core Operating Income up 12.6% fueled by strong top-line growth
• Core diluted EPS of €1.74, up 16.0%

Ipsen and Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, today announced that Teijin Pharma has filed a supplemental application with Pharmaceuticals and Medical Devices Agency to use Ipsen’s subcutaneous drug Somatuline^® (lanreotide) for the treatment of neuroendocrine tumors (NETs). The drug is currently available in Japan as a treatment for acromegaly and pituitary gigantism.

• CHMP recommends approval of Cabometyx™ (cabozantinib) for the treatment of advanced renal cell carcinoma (RCC) in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy based on the results of a large, randomized Phase 3 trial, METEOR.
• Cabometyx™ (cabozantinib) is the first and only multi-kinase inhibitor with established clinical benefits demonstrated for all three key efficacy endpoints: overall survival (OS), progression-free survival (PFS) and objective response rate (ORR).
• Cabometyx™ (cabozantinib) significantly improved overall survival across all evaluated patient subgroups.

Ipsen today announced that the European Medicines Agency (EMA), the European regulatory authority, has accepted the submission of filing for telotristat etiprate as an adjunct to somatostatin analogue therapy for the long-term treatment of carcinoid syndrome to improve symptom control in adult patients with metastatic neuroendocrine tumors.

The Board of Directors of Ipsen, met on 8 July 2016, and has appointed David Meek as Chief Executive Officer, effective July 18, 2016. On this date, Marc de Garidel will assume the role of non-executive chairman and will continue to serve the Board of Directors through his deep industry expertise. In addition, Marc de Garidel will advise Mayroy, the Ipsen controlling holding company.

Ipsen, a global specialty-driven pharmaceutical group, announced today the successful issue of its inaugural unsecured 7-year Notes for a total of €300 million.
These Notes mature on June 16, 2023 and pay interest at an annual rate of 1.875%. Application has been made for the Notes to be admitted to trading on the regulated market of Euronext Paris.

Ipsen announces the launch of an employee shareholding plan. This plan aims to align employees with the Group’s development and performance.

Additional data from pivotal METEOR trial underscore clinically meaningful benefit of CABOMETYX™ across subgroups of patients

• Details of clinically meaningful increase in overall survival from METEOR trial to be presented in an oral abstract session and published simultaneously in The Lancet Oncology
• Overall survival and progression-free survival benefits consistent across all subgroups evaluated

Ipsen today announced the appointment of Eugenia Litz as Vice President Investor Relations for the Ipsen Group, effective today. She will report to Aymeric Le Chatelier, Executive Vice President, Chief Financial Officer.
Eugenia Litz takes over Stéphane Durant des Aulnois nominated Finance Director Iberia.
Eugenia will manage the Ipsen Group financial communication and build strong relations with investors and the financial community.

Ipsen in collaboration with Exelixis will share these results with European regulatory authorities and evaluate potential next steps in development and submission strategy for cabozantinib as a treatment of first-line advanced renal cell carcinoma

Scientists will study the intracellular trafficking of botulinum neurotoxins within neurons

• Oncodesign is becoming a strategic partner for Ipsen in preclinical pharmacology for its oncology research programs
• Oncodesign teams are moving to Ipsen’s private open innovation campus in Paris-Saclay

• Group sales up 4.7%¹
  • Specialty care sales up 9.7%¹, driven by the accelerated growth of Somatuline^® in neuroendocrine tumors
  • Primary care sales down 11.0%¹ , impacted by the slowdown in international markets
• 2016 financial objectives confirmed

Ipsen and Probi today jointly announced the signature of a license and supply agreement for the commercialization of Probi’s probiotic strain Lactobacillus plantarum 299v (LP299V^® ). The agreement covers 18 countries, primarily within EU and emerging markets. This clinicallydocumented probiotic with patents in the gastro-intestinal field is expected to complement Ipsen’s strong medical portfolio in gastroenterology. From Probi’s perspective it could become one of the largest distribution agreements so far, and is of high strategic importance for both companies.

CABOMETYX™ (cabozantinib) is the first therapy to demonstrate improved overall survival, progression-free survival and objective response rate in a large, randomized phase 3 trial of patients with advanced kidney cancer.

In February 2016, Exelixis and Ipsen entered into an exclusive licensing agreement to develop and commercialize cabozantinib in regions outside the United States, Canada and Japan.

Leveraging its instrumental contribution to the BioIntelligence consortium, Ipsen has decided to deploy the 3DEXPERIENCE platform.

Ipsen announced today that its 2015 Registration Document has been filed with the French “Autorité des Marchés Financiers” (AMF) on 29 March 2016 and registered under the number D.16-0216.

• Research partnership for novel therapeutic peptides targeting a transmembrane receptor overexpressed in a large number of cancers and implicated in their development.
• Option for Ipsen to acquire the exclusive rights to develop and market the new drug candidates.

• Operating performance in line with guidance, with Group sales up 10.4%1 and Core Operating Income up 23.8%
• Core diluted EPS of €2.78, up 25.3%, and sound cash flow generation with closing cash of €214.0 million
• Proposal of a dividend of €0.85 per share

• Cabozantinib commercialized for medullary thyroid cancer (MTC) and filed for advanced renal cell carcinoma (RCC)
• $200 million upfront payment and subsequent regulatory and commercial milestones

Ipsen strengthens its radiopharmaceuticals pipeline in niche oncology indications.

• Separation of functions between Chairman and Chief Executive Officer (CEO)
• Search under way for a new CEO
• Marc de Garidel, Chairman & CEO of Ipsen, to become nonexecutive Chairman upon arrival of new CEO
• Departure of Deputy CEO Christel Bories

Single injections of both Dysport^® (abobotulinumtoxinA) doses (10U/kg/leg and 15U/kg/leg) significantly reduce muscle hypertonia and spasticity translating into clinical and functional benefits.

Ipsen acquires the intellectual property for Galderma’s liquid toxin in some key Asia-Pacific territories (APAC¹ ).